Krishnansu Sujata Tewari

picture of Krishnansu Sujata Tewari

Professor, Division of Gynecologic Oncology, Obstetrics & Gynecology
School of Medicine

Director, Division of Gynecologic Oncology, Obstetrics & Gynecology
School of Medicine

Director, Fellowship Program, Division of Gynecologic Oncology, Obstetrics & Gynecology
School of Medicine

The Philip J. DiSaia, MD Chair in Gynecologic Oncology, Obstetrics & Gynecology
School of Medicine


Fellowship, University of California, Irvine, 2002, Gynecologic Oncology
Residency, University of California, Irvine, 1998, Obstetrics and Gynecology
M.D., University of California, Irvine, 1994, Medicine
B.S., University of California, Berkeley, 1990, Molecular Biology

Phone: (714) 456-8020
Fax: (714) 456-6632
Email: ktewari@hs.uci.edu

University of California, Irvine
333 City Blvd. West
Suite 1400
Mail Code: 3200
Orange, CA 92868
URL
Academic Distinctions
AWARDS and HONORS

2010-2020 Best Doctors in America Designation
2012-2020 Top Doctor, U.S. News & World Report
2008-2020 Orange Coast Magazine Physician of Excellence, Orange County Med
Association
2018 Resident Teaching Award, UC Irvine Dept of Obstetrics & Gynecology
2013 SGO 2013 Presidential Award for Most Outstanding Abstract (Abstract
#1)
2013 SGO 2013 Hugh Barber Lectureship Designation for GOG 240
(Abstract #1)
2010 Marquis Who’s Who in America Designation
2007 Nominated for ARISE Award – UC Irvine Medical Center
2007 Thomas J Garite, MD Faculty Teaching Award – UC Irvine
2007 American Journal of Obstetrics & Gynecology Top 5% Peer Reviewer
2006 Distinguished Expert Series – Article Designation
“Ovulatory failure and fertility preservation” {Eur J Gynaecol Oncol}
2006 John Molitor MD Volunteer Clinical Faculty Award – UCIMC
2005 Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
2004 Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
2003 Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
2000 1st Prize Award, $5,000.00, International Gynecologic Cancer Society
Association of the Argentinian Knights of the Sovereign & Military Order
of Malta
2000 Distinguished Expert Series – Article Designation
Treatment of ovarian germ cell tumours” {Eur J gynaecol Oncol}
2000 Philip J. DiSaia Society Resident Mentorship Award
2000 American Radium Society Young Oncologist Award
1999 Continuing Medical Education – Article Designation “Managing cervical
cancer in pregnancy” {Contemp Ob/Gyn}
1994 Upjohn foundation Award for Academic Excellence
1994 Alfred H. Edwards, MD Memorial Scholarship Award UCI Medical
Alumni Association
1994 Senior Humanitarian Award – Medical Students of UCI COM
1994 Educational Affairs Service Award – UCI College of Medicine
1983 Alumni Scholar, UC Berkeley
Appointments
2012 – present
Professor with Tenure
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine Medical Center

2006 – 2012
Associate Professor of Clinical X
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine Medical Center

2002-2006
Assistant Clinical Professor
Volunteer Faculty - Department of Obstetrics & Gynecology
University of California, Irvine Medical Center

1998-2002
Clinical Instructor
Fellow – The Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine Medical Center

NON-ACADEMIC APPOINTMENTS

2011-present
Director, Gynecologic Oncology Program
Center for Cancer Prevention & Treatment
St. Joseph’s Medical Center
Orange, CA

2002-2006
Gynecologic Oncologist
Kaiser Foundation Hospitals
Riverside, Baldwin Park, Bellflower and Harbor City, CA
Research Abstract
Research Support and/or Scholastic Performance
Ongoing
NCT00803062 Tewari (PI) 01/01/2020-12/31/2021
National Cancer Institute (Joe Biden Cancer Moonshot)
GOG0240: Molecular characterization of exception responders and long-term survivors of advanced cervical cancer treated with chemotherapy doublets with or without angio-genesis therapy
Role: PI

MK-3475-826 Tewari (PI) 10/31/2018 – 10/30/2021
Merck Sharp & Dohme Corp.
UCI 18-32: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE- 826)
Role: PI

CO-338-043 Tewari (PI) 12/12/2016 – 01/11/2022
Clovis Oncology, INC
UCI 16-69: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M13-694 Tewari (PI) 02/16/2016 – 02/15/2021
Gynecologic Oncology Group
GOG-3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: PI

YO39523 Tewari (PI) 02/01/2018 – 04/30/2020
Gynecologic Oncology Group
GOG-3015: A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: PI

R2810-ONC-1676 Tewari (PI) 05/23/2018 – 02/28/2021
Gynecologic Oncology Group
GOG-3016: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma
Role: PI

VB-111-701 Tewari (PI) 07/02/2019 – 03/31/2022
Gynecologic Oncology Group
GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the
Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Role: PI

GCT1015-05 Tewari (PI) 03/15/2019 – 12/31/2022
Gynecologic Oncology Group
GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMaxTFADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Role: PI

D081RC00001 Tewari (PI) 05/20/2019 – 02/28/2022
Astrazeneca PLC
GOG 3025: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Role: PI

ECOG-EAY131 Bota (PI) 03/01/2019 – 02/28/2025
ECOG-ACRIN
Molecular Analysis for Therapy Choice (MATCH)
Role: Co-Investigator

SWOG-S1609 Bota (PI) 03/01/2014 – 02/28/2025
SWOG
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Role: Co-Investigator

GOG-0238 Tewari (PI) 03/01/2014 – 02/28/2025
GOG
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Role: PI

GOG-0263 Tewari (PI) 03/01/2014 – 02/28/2025
GOG
Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Role: PI

GOG-0270 Tewari (PI) 03/01/2014 – 02/28/2025
GOG
GROningen INternational Study on Sentinel nodes in Vulvar cancer
Role: PI

GOG-0274 Tewari (PI) 03/01/2014 – 02/28/2025
GOG A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902/GOG-0274/RTOG 1174)
Role: PI

GOG-0278 Tewari (PI) 03/01/2014 – 02/28/2025
GOG
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer
Role: PI

GOG-0279 Tewari (PI) 03/01/2014 – 02/28/2025
GOG
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva
Role: PI

GOG-0724 Tewari (PI) 03/01/2014 – 02/28/2025
NRG Oncology
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Role: PI

GOG-3028 Tewari (PI) 11/13/2019 – 11/30/2022
GOG Foundation
A Two-Arm, Randomized, Non-Comparative, Phase II Trial of AGEN2034 (anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Role: PI

GOG-3032 Cappuccini (PI) 09/03/2019 – 09/02/2022
GOG Foundation
A Phase II Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Role: Co-Investigator

NRG-GY006 Tewari (PI) 03/01/2014 – 02/28/2025
NRG Oncology
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Role: PI

NRG-GY009 Tewari (PI) 03/01/2014 – 02/28/2025
NRG Oncology
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
Role: PI

NRG-GY014 Cappuccini (PI) 07/23/2019 – 02/28/2025
NRG Oncology
A Phase II Study of Tazemetostat in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Role: Co-Investigator

NRG-GY018 Tewari (PI) 03/01/2014 – 02/28/2025
NRG Oncology
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVa, Stage IVb or Recurrent Endometrial Cancer
Role: PI

NRG-GY021 Tewari (PI) 12/23/2019 – 02/28/2025
NRG Oncology
A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Patients in Platinum-Sensitive Recurrent Ovarian Cancer
Role: PI

UCI-15-31 Tewari (PI) 12/10/2015 – 12/09/2021
Morphotek, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Role: PI

UCI-17-111 Tseng (PI) 07/26/2018 – 06/30/2021
On Target Laboratories, LLC.
A Phase III, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Role: Co-Investigator

UCI-18-19 Zhu (PI) 08/27/2018 – 08/26/2021
Innovent Biologics (Suzhou) Co. Ltd.
An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies
Role: Co-Investigator


UCI-18-86 Cappuccini (PI) 08/08/2019 – 08/07/2022
AstraZeneca A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women with Locally Cervical Cancer (CALLA)
Role: Co-Investigator

UCI-18-91 Cappuccini (PI) 01/18/2019 – 10/31/2021
AIVITA Biomedical, Inc.
Phase II, Double-Blind, Randomized Trial of AVOVA-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) vs. Autologous Peripheral Blood Mononuclear Cells (MC) in Patients with Stage III or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma After Primary Therapy
Role: Co-Investigator

UCI-19-86 Tewari (PI) 02/01/2020 – 01/31/2023
Corcept Therapeutics
A Phase II, Randomized, Open-label, 3-Arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Role: PI


Completed (last five years)

GOG-0237 Tewari (PI) 05/14/2009 – 08/22/2018
GOG
Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Role: PI

NIH R21 Tewari (PI) 1/1/2011 – 12/31/2015
CA156032.
Novel biologic markers of treatment resistance in locally advanced cervical carcinoma using tumor samples obtained on two phase 3 randomized trials of chemoradiation in women with locally advanced cervical cancer. (GOG 191 and GOG 219).
Role: PI

GOG-0286B Tewari (PI) 11/17/2014 – 02/01/2018
GOG
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Role: PI

UCI-13-54 Tewari (PI) 05/09/2014 – 09/15/2017
UCI
A Phase I Dose-Escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Role: PI
Publications
BOOK CHAPTERS

1. Tewari KS. Vulvar neoplasia. In: Cancer Diagnosis and Early Prevention in Women, Manetta A (ed). Mosby Publication, 2003.

2. Tewari KS. The adventure of the three abnormal Paps. In: The Best of After Office Hours, Pitkin RM, Rinehart RD (eds). The American College of Obstetrics & Gynecology, 2003.

3. Berman ML, DiSaia PJ and Tewari KS. Pelvic malignancies, Gestational Trophoblastic Neoplasia, and Nonpelvic malignancies. Chapter 58, pp.1213-1242. In: Maternal-Fetal Medicine: Principles and Practice, Ed 5, Creasy RK, Resnik R (eds). Saunders, Philadelphia, Pennsylvania, 2004.

4. Tewari KS, Berman ML. Cytoreductive Surgery in the Left Upper Abdomen. In: Surgery for Ovarian Cancer: Principles and Practice. Bristow RE, Karlan BY (eds), Taylor & Francis, 2005.

5. Tewari KS, Monk BJ. Tumors of the Cervix. In: Textbook of Uncommon Cancers, Ed 3, Raghaven D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA (eds). Wiley, 2006.

6. Tewari KS. Cancer in Pregnancy. In: Clinical Gynecologic Oncology, 7th Ed, DiSaia PJ, Creasman WT (eds) Mosby Elsevier, 2007.

7. Monk BJ, Tewari KS. Invasive Cervical Cancer. In: Clinical Gynecologic Oncology, 7th Ed, DiSaia PJ, Creasman WT (eds) 2007, Mosby Elsevier, 2007.

8. Tewari KS, Berman ML. A Brief History of Gynecologic Oncology in the United States. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 43, European Society of Gynecologic Oncology, 1st Ed, Ayhan A, Gultekin, M (eds), 2009.

9. Monk BJ, Tewari KS. The Spectrum and Clinical Sequelae of Human Papillomavirus Infection. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 72, European Society of Gynecologic Oncology, 1st Ed, Ayhan A, Gultekin, M (eds), 2009.

10. Martinez A, Tewari KS, Ferron G, Ramirez PT. Cytoreductive Surgery: Upper Abdomen – Left Hypochondriac and Epigastric Regions. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd Edition. Bristow RE, Karlan BY, Chi DS (eds), Informa Healthcare, 2010.

11. Tewari KS. Cancer in Pregnancy. In: DiSaia & Creasman’s Clinical Gynecologic Oncology, 8th Ed, McMeekin SD, Mutch (eds), 2011.

12. Tewari KS, Monk BJ. Invasive Cervical Cancer. In: DiSaia & Creasman’s Clinical Gynecologic Oncology, 8th Ed, McMeekin SD, Mutch (eds), 2011.

13. Tewari KS, Brewster WR. Clinical Trials. In: Surgical Atlas of Gynecologic Oncology, 1st Ed, Bristow RE, Karlan BY (eds), 2011.

14. Tewari KS. Neoplasia in Pregnancy. In: University of California, Obstetrics & Gynecology, Women’s Health Review. DiSaia PJ (ed), 2011.

15. Tewari KS, Monk BJ. Invasive Cervical Cancer. In: University of California, Obstetrics & Gynecology, Women’s Health Review. DiSaia PJ (ed), 2011.

16. Tewari KS, Berman ML. A Brief History of Gynecologic Oncology in the United States. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 43, European Society of Gynecologic Oncology, 2nd Ed, Ayhan A, Gultekin, M (eds), 2011.

17. Tewari KS, Monk BJ. The Spectrum and Clinical Sequelae of Human Papillomavirus Infection. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 72, European Society of Gynecologic Oncology, 2nd Ed, Ayhan A, Gultekin, M (eds), 2011.

18. Tewari KS, Monk BJ. Tumors of the Cervix. In: Textbook of Uncommon Cancers, Ed 4, Raghaven D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA (eds). Wiley, 2011.

19. Tewari KS. History of radical pelvic surgery. Radical Pelvic Surgery in Gynecologic Oncology. Bristow RE (ed), Elsevier (in production).

20. Tewari KS, Monk BJ. 21st Century Clinical Ovarian Cancer. Springer Healthcare LLC (in production).

21. Tewari KS, Monk BJ. 21st Century Clinical Cervical Cancer. Springer Healthcare LLC (in development).

22. Tewari KS. History of ovarian cancer surgery. In: Surgery for Ovarian Cancer: Principles and Practice, 3rd edition. Bristow RE, Karlan BY, Chi D (eds).

23. Tewari KS. Etiology and pathogenesis of cervical cancer. Chapter 2.2. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

24. Tewari KS. Screening and prevention of cervical cancer. Chapter 3.2. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

25. Tewari KS. Case study in cervical cancer. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

26. Tewari KS, Burger RA. Handbook on targeted therapy in gynecologic malignancies. (in development)

27. Tewari KS, Penson RT, Monk BJ. Tumors of the Ovary and Fallopian Tube. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practices of Oncology. DeVita Jr, Vincent T, Rosenberg, Steven A, et al (eds). LWW, Eleventh edition, 2018.

JOURNAL ARTICLES, PEER REVIEWED

1. Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Syed AMN and DiSaia PJ. Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. Gynecol Oncol 1994;52:222-8.

2. Monk BJ, Tewari K, Gamboa-Vujicic G, Burger RA, Manetta A and Berman ML. Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy? Obstet Gynecol 1995;85:343-8.

3. Tewari K, Steiger RM, Monk BJ, Scannell G, Tominaga G and Waxman K. Should critical care medicine be a formal part of the undergraduate curriculum? J Intensive Care Med 1996;11:13-8.

4. Tewari K, Wold SM and Asrat T. Septic shock in pregnancy associated with legionella pneumonia. Am J Obstet Gynecol 1997;176:706-7.

5. Manetta A, Tewari K and Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature. Gynecol Oncol 1997;66:20-6.

6. Cappuccini F, Tewari K, Rogers LW and DiSaia PJ. Extramammary Paget’s disease of the vulva: Metastases to the bone marrow in the absence of an underlying adenocarcinoma – Case report and literature review. Gynecol Oncol 1997;66:146-50.

7. Tewari K, Bonebrake RG, Asrat T and Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero secondary to inflammatory breast cancer during pregnancy. Lancet 1997;350:183.

8. Tewari K, Brewer C, Cappuccini F, Macri C, Rogers LW and Berman ML. Advanced stage small cell carcinoma of the ovary in pregnancy: Long-term survival after surgical debulking and multi-agent chemotherapy. Gynecol Oncol 1997;66:531-4.

9. Monk BJ, Tewari K, Burger RA, Johnson MT, Montz FJ and Berman ML. A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer. Gynecol Oncol 1997;67:241-7.

10. Tewari K, Rose GS, Balderston KD, Porto M and Kohler MF. Fertility drugs and malignant germ cell tumour of the ovary in pregnancy. Lancet 1998;351:957-8.

11. Tewari K, Cappuccini F, Gambino A, Kohler MF, Pecorelli S and DiSaia PJ. Neoadjuvant chemotherapy in the management of locally advanced cervical carcinoma in pregnancy: A report of two cases and review of issues specific to the management of cervical cancer in pregnancy, including, planned delay of therapy. Cancer 1998;82:1529-34.

12. Tio I, Tewari K, Balderston KD, Milliken JC and Porto M. Emergency mitral valve replacement in the setting of severe pulmonary hypertension and acute cardiovascular decompensation following evacuation of twins at fifteen weeks’ gestation. Am J Obstet Gynecol 1998;179:270-2.

13. Cappuccini F, Tewari K, Fuller PN, Pindur A and DiSaia PJ. Aggressive clinical behavior of a rare uterine sarcoma. Gynecol Oncol 1998;70:147-51.

14. Tewari K, Balderston KD, Carpenter SE and Major CA. Papillary thyroid carcinoma manifesting as a thyroid storm in pregnancy. Am J Obstet Gynecol 1998;179:818-9.

15. Balderston KD, Tewari K, Azizi F and Yu JK. Intrahepatic cholangiocarcinoma masquerading as the syndrome of hemolysis, elevated liver enzymes and low platelets of pregnancy. Am J Obstet Gynecol 1998;179:823-4.

16. Balderston KD, Tewari K, Gregory WT, Berman ML and Kucera PR. Neuroendocrine small cell carcinoma of the uterine cervix in pregnancy: Long-term survival following combined therapy. Gynecol Oncol 1998;71:128-32.

17. Tewari K, Cappuccini F, Balderston KD, Rose GS, Porto M and Berman ML. Pregnancy in a Jehovah’s Witness with cervical cancer and anemia. Gynecol Oncol 1998;71:330-2.

18. Taylor JA, Tewari K, Liao SY, Hughes CCW and Villarreal LP. Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice. J Virol 1999;73:5144-8.

19. Moore MM, Tewari K, Rose GS, Freuhauf JP and DiSaia PJ. Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient. Gynecol Oncol 1999;73:452-4.

20. Tewari K, Cappuccini F, Syed AMN, Puthawala AA, DiSaia PJ, Berman ML, Manetta A and Monk BJ. Interstitial brachytherapy in the treatment of locally advanced and recurrent vulvar cancer. Am J Obstet Gynecol 1999;181:91-8.

21. Tewari K, Cappuccini F, Rosen RB, Rosenthal J, Asrat T and Kohler MF. Relapse of acute lymphoblastic leukemia in pregnancy: Survival following chemoirradiation and autologous transfer of interleukin-2 activated stem cells. Gynecol Oncol 1999;74:143-6.

22. Tewari K, Cappuccini F, Brewster WR, DiSaia PJ, Berman ML, Manetta A, Puthawala AA, Syed AMN and Kohler MF. Interstitial brachytherapy for vaginal recurrences of endometrial cancer. Gynecol Oncol 1999;74:416-22.

23. Tewari K, Asrat T, Ruttgers JKL and Nageotte MP. The evolution of linitis plastica as a consequence of advanced gastric carcinoma in pregnancy. Am J Obstet Gynecol 1999;181:757-8.

24. Tewari K and DiSaia PJ. Authors’ reply to “Comment on: Neoadjuvant chemotherapy for the management of locally advanced cervical carcinoma in pregnancy.” (Letter) Cancer 1999;85:1203-4.

25. Tewari K and Manetta A. In vitro chemosensitivity testing and mechanisms of drug resistance in epithelial ovarian cancer. Curr Oncol Rep 1999;1:77-84.

26. Tewari K, Cappuccini F, DiSaia PJ, Berman ML, Manetta A and Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000;95:128-33.

27. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, Hughes CCW and Villarreal LP. Development and assessement of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48.

28. Tewari KS, Cappuccini F, Asrat T, Flamm BL, Carpenter SE, DiSaia PJ and Quilligan EJ. Obstetrical emergencies precipitated by malignant brain tumors. Am J Obstet Gynecol 2000;182:1215-21.

29. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu I-R, Burger RA, DiSaia PJ and Fruehauf JP. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 2000;78:130-6.

30. Tewari KS. The adventure of the three abnormal PAPs. Obstet Gynecol 2000;96:795-8.

31. Tewari KS and DiSaia PJ. On the evolution of a successful treatment program for a solid tumour system. Eur J Gynaecol Oncol 2000;21:339-47.

32. Tewari KS, Cappuccini F, Puthawala AA, Kuo JV, Burger RA, Monk BJ, Manetta A, Berman ML, DiSaia PJ and Syed AMN. Primary invasive carcinoma of the vagina: Treatment with interstitial brachytherapy. Cancer 2001;91:758-70.

33. Tewari KS, Steiger RM, Lam MM, Ruttgers JKL, Berkson RA and DiSaia PJ. Bilateral pheochromocytomas in pregnancy heralding multiple endocrine neoplasia syndrome IIA. J Reprod Med J Reprod Med. 2001;46:385-8.

34. Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD and Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001;97:707-111.

35. DiSaia PJ and Tewari KS. Recent advancements in the treatment of epithelial ovarian cancer. J Obstet Gynaecol Res 2001;27:61-75.

36. Naylor CS, Tewari K and Asrat T. Trisomy 13 in one fetus from a twin gestation after intracytoplasmic sperm injection. J Reprod Med 2001 46:497-8.

37. Tewari KS and DiSaia PJ. Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res 2002;28:123-40.

38. Tewari KS and DiSaia PJ. Lung and bronchus cancer in women: A 21st Century epidemic. Clin Obstet Gynecol 2002;45:784-811.

39. Monk BJ, Tewari KS, Puthawala AA, Syed AMN, Haugen JA, Burger RA. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys 2002;52:806-15.

40. Tewari KS and DiSaia PJ. Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy. Obstet Gynecol Clin North Am 2002 29:843-68.

41. Syed AMN, Puthawala AA, Abdelaziz NN, el-Naggar M, DiSaia PJ, Berman ML, Tewari KS, Sharma A, Londre A, Juwadi S, Cherlow JM, Damore S and Chen YJ. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54:67-78.

42. Berg JC, Tewari KS, Del Rosario R and Berman ML. Unusual presentation of a malignant granular cell tumor of the pelvis: Case report and literature review. Gynecol Oncol 2003;90:224-30.

43. Geas FL, Tewari DS, Rutgers JKL, Tewari KS and Berman ML. Surgical cytoreduction and hormonal therapy of an advanced endometrioid stromal sarcoma of the ovary. Obstet Gynecol 2004;103:1051-4.

44. Tewari KS, Mehta RS, Burger RA, Kyshtoobayeva AS, Yu I-R, Monk BJ, Manetta A, Berman ML, DiSaia PJ and Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian cancer. Gynecologic Oncology, 2005;98:360-8.

45. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical carcinoma. Curr Oncol Rep, 2005;7:419-34.

46. Tewari KS, DiSaia PJ. Ovulatory failure, fertility preservation and reproductive strategies in the setting of gynecologic and non-gynecologic malignancies. Eur J Gynaecol Oncol 2006;27:449-61.

47. Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol 2007; 25:2952-65.

48. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007;107:S6-13.

49. Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 2008;98:111-6.

50. Chase DM, Monk BJ, Wenzel LB, Tewari KS. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther 2008;8:227-41.

51. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: Screening and management of preinvasive disease. 2008;199:3-9.

52. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: Current treatment of invasive disease. Am J Obstet Gynecol 2008;199:10-8.

53. Meltzer S, Monk BJ, Tewari KS. Green tea catechins in the treatment of external genital warts. Am J Obstet Gynecol 2009;200:233.e1-7. Epub 2008 Nov 18.

54. Monk BJ, Tewari KS. Sentinel lymph node dissection in vulvar carcinoma: What is the acceptable false-negative rate? Oncologist 2008;22:538-42.

55. Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol 2009;112:85-9.

56. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: Trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170-80.

57. Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: A 20-year experience. Int J Gynecol Cancer 2009;19:1080-4.

58. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie 2009;32:552-4.

59. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol 2009;115:339-42.

60. Kalantari M, Chase DM, Tewari KS, Bernard H-U. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: A pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression.. J Med Virology 2010;82:311-20.

61. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: Commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.

62. Tewari KS. Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Expert Panel. Clin Ovarian Cancer 2011;4:90-3.

63. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.

64. Chase DM, Mathur N, Tewari KS. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov 2010;5:251-60.

65. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group study. Gynecol Oncol 2010;119:444-50.

66. Eskander RN, Randall LM, Berman ML, Tewari KS, DiSaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011;205:103-10.

67. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Miller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. Int J Gynecol Cancer 2010;20:1137-41.

68. Tewari KS, Monk BJ. American Society of Clinical Oncology 2011 Annual Meeting update. Summary of selected gynecologic cancer abstracts. Gynecol Oncol 2011;122:209-12.

69. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stromal invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study. Gynecol Oncol 2012 125:87-93. Epub 2011 Dec 8.

70. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther 2012;12:51-62.

71. Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Women’s Health 2012;4:395-404.

72. Eskander RN, Tewari KS. Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian, and cervical cancer: A systematic review. J Hematol Malig 2012;2:63-73.

73. Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. The challenge of follow-up in a low-income colposcopy clinic: Characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis 2012;16:345-51.

74. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127:345-50.

75. Tewari KS. Advanced cytoreductive surgery workshop report. Int J Gynecol Cancer 2012;22:1604-10.

76. Tewari KS. American Society of Clinical Oncology 2012 Annual Meeting: Highlights from the Gynecologic Oncology Track. Int J Gynecol Cancer 2012;22:1634-9.

77. Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, DiSaia PJ, Berman ML, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen WP, McLaren CE. Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: Long-term results. Int J Radiat Oncol Biol Phys 2013;85:714-20.

78. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in Gynecologic Oncology: Impact on patient care and treatment. In J Gynecol Pathol 2013;32:293-8.

79. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecolgoic Oncology Group study. Gynecol Oncol 2013;129:486-94.

80. Brueseke TJ, Tewari KS. Toll-like receptor 8: Augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol 2013;5:13-9.

81. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munrose DG, Ueland FR. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol 2013;209:581.e1-8.

82. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol 2013;5(Suppl 1):55-61.

83. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol 2014;132:221-6.

84. DiSilvestro P, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: A Gynecologic Oncology Group study. J Clin Oncol 2014;32:458-64.

85. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma – Mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014;132:496-505.

86. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU. Methylation of human papillomavirus 16, 18, 31, 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology 2014;448:314-21.

87. EskanderRN, Tewari KS. American Society of Clinical Oncology 2013: Summary of scientific achievements in gynecologic cancer. Int J Gynecol Cancer 2014;24:13-8.

88. Tewari KS, Sill MW, Long III HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:34-43.

89. Tewari KS. New world order(s): Healthcare metrics, international borders, and gravitational waves. Gynecol Oncol 2014;133:139-41.

90. Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. Gynecol Oncol 2014;133:439-45.

91. Eskander RN, Osann K, Dickson E, Holman L, Rauh-Hain A, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. Assessment of palliative care training in Gynecologic Oncology: A A Gynecologic Oncology Fellow Research Network Study. Gynecol Oncol 2014;134:379-84.

92. Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol 2014;7:613-22.

93. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol 2014;26:314-21.

94. Eskander RN, Tewari KS. Beyond angiogenesis blockade: Targeted therapy for advanced cervical cancer. J Gynecol Oncol 2014; 25:249-59.

95. Long B, Eskander RN, Tewari KS. The use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A Review. World J Radiol 2014;6:366-73.

96. Miller DS, Blessing JA, Ramondetta LM, Pham HT, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: A limited access phase II trial of the Gynecologic Oncology Group.. J Clin Oncol 2014;32:2744-9.

97. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol 2014;32:2687-90.

98. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol 2014;6:280-92.

99. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Iouri Ivanov, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SL, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings in risk-reducing salpino-oophorectomy (RRSO): Primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014;32:3275-83.

100. Tewari KS, Tracy L, DiSaia PJ. Full-thickness skin grafts for neovaginal construction in Mayer-Rokitansky-Kuster-Hauser syndrome. Description of surgical technique and early results. J Gynecol Surg 2015;31:52-7.

101. Tewari KS, Monk BJ. New strategies in advanced cervical cancer: From angiogenesis blockade to immunotherapy. Clin Cancer Res 2014;20:5349-58.

102. Eskander RN, Tewari KS. Exploiting the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol 2014;7:847-58.

103. Tewari KS, Monk BJ. Development of a platform for systemic anti-angiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol 2014;12:737-48.

104. Gibson SJ, Tewari KS, Monk BJ, Chase DM. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract 2014; Sept 30.

105. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: Pharmacohynamic modeling, survival impact, and toxicology. Future Oncol 2015;11:909-22.

106. Krill L, Tewari KS. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clin Ther 2015;37:9-19.

107. Eskander RN, Tewari KS. Immunotherapy: An evolving paradigm in the treatment of advanced cervical cancer. Clin Ther 2015;37:20-38.

108. Long BJ, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the healthcare system on the treatment of advanced stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.e1-9.

109. Krill L, Tewari KS. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother 2015;16:675-83.

110. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Sill MW, Long III HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJA, Leitao MM, Michael HE, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase III trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301-11.

111. Minion LE, Bai J, Monk BJ, Keller RL, Eskander RN, Forde GK, Chan JK, Tewari KS. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol 2015;137:490-6.

112. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91.

113. Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE. Costs of treatment of elderly women with advanced ovarian cancer in a Medicare population. Gynecol Oncol 2015;137:479-84.

114. Cripe J, Eskander RN, Tewari KS. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol 2015;6:16-21.

115. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 mutation in the first report of a Vietnamese American kindred with Lynch Syndrome. Gynecol Oncol Rep 2015;12:31-3.

116. Liu FW, Cripe J, Tewari KS. Antiangiogenesis therapy in gynecologic malignancies. Oncology 2015;29:350-60.

117. Wolford JE, Tewari KS. US FDA Oncology Drug Approvals in 2014. Future Oncol 2015;22:1-15.

118. Tewari KS, Eskander RN, Monk BJ. Development of olaparib for BRCA deficient recurrent epithelial ovarian cancer. Clin Cancer Res 2015;21:3829-35.

119. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214:22-30.

120. Tewari KS. Clinical implications of cediranib in advanced cervical cancer. Lancet Oncol 2015;16:1447-8.

121. Longoria TC, Tewari KS. Pharmacologic management of advanced cervical cancer: Antiangiogenesis therapy and immunotherapeutic considerations. Drugs 2015;75:1853-65.

122. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol 2016;27:114-21.

123. Hodeib M, Serna-Gallegos T, Tewari KS. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity – CLEOPATRA and PENELOPE. Future Oncol 2015;11:3113-31.

124. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ 3rd, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemothehrapy with/without bevacizumab: NRG Oncology/GOG study. Clin Cancer Res 2015;21:5480-7.

125. Alldredge JK, Tewari KS. Clinical trials of anti-angiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist 2016; 21:576-85.

126. Liu FW, Tewari KS. New targeted agents in gynecologic cancers: Synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Options Oncol 2016;17:12.

127. LaFargue CJ, Tewari KS. Recent patents for homologous recombination deficiency assays among women with ovarian cancer. Recent Pat Biotechnol 2016;9:86-101.

128. Monk BJ, Sill M, Walker J, DiSilvestro P, Sutton G, Tewari KS, Pajon E, Martin L, Schilder J, Coleman R, Balkissoon J, Aghajanian C. Randomized phase II evaluation of bevacizuamb versus bevacizumab/fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2016;34:2279-86.

129. Monk BJ, Herzog TJ, Tewari KS. Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients. Curr Pharm Des 2016;22:4717-28.

130. Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 2016; 12:1247-53.

131. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol 2016;143:294-301.

132. Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ. Does the time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol 2016;143:484-9.

133. Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O’Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol 2016;143:460-5.

134. Minion LE, Tewari KS. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther 2017;17:191-8.

135. Rungruang B, Miller A, Krivak TC, Horowitz N, Rodriguez N, Hamilton CA, Backes FJ, Carson L, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer 2017;123:985-93.

136. Tewari KS. Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract 2016 Oct 24;3:10.

137. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Wwalker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacziumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol 2017;18:779-91.

138. Reyes HD, Miecznikowski J, Gonzelez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2017;146:247-53.

139. Chan JK, Deng W, Higgins R, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Weldon C, Monk BJ, Aghajanian C. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic study. Gynecol Oncol 2017;146:554-9.

140. Tewari KS, Sill MW, Penson RT, Long III HJ, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Sehman FB, Blessing JA, Brady MF, Burger RA, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh W-J, Monk BJ. Final overall survival of the phase III randomised trial of chemotherapy with and without bevacizumab for advanced cervical cancer: A NRG Oncology/Gynecologic Oncology Group study. Lancet 2017;390:1654-63.

141. Wolford JE, Tewari KS. Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clincial Oncology. J Gynecol Oncol 2017;28:e74.doi:10.3802/jgo.2017.28.e74.

142. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 2017;147:243-9.

143. Moore KN, Tritchler D, Kaufman K, Lankes HA, Quinn MC, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: A NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2017 (accepted).

144. Horowitz NS, Maxwell LG, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: A NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 2018;148:49-55.

145. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casedei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: A NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 2018;24:777-83.

146. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM. Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumor histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer 2018;118:162-70.

147. Serna-Gallegos TR, LaFargue CJ, Tewari KS. The ecstacy of gold: patient expirations for trastuzumab, bevacizumab, rituximab, and cetuximab. Recent Pat Biotechnol 2017;12:101-12.

148. Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract 2018 Jan 5;5:1.doi:10.1186/s40661-017-0058-5.

149. Wolford JE, Tewari KS. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opin Drug Discov 2018;13:445-57.

150. Minion LE, Tewari KS. Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 2018;148:609-21.

151. Eskander RN, J Kauderer J, Tewari KS, Bristow RE, Burger RA. Correlation between surgeon’s assessment of residual disease and findings on postoperative pretreatment computed tomography scans in women with advanced stage ovarian cancer reported to have undergone optimal cytoreduction: A NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2018;149:525-30.

152. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O’Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Devine LA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in
advanced/recurrent endometrial cancer. Gynecol Oncol 2018;150:274-81.

153. Gordon C, Carmichael JC, Tewari KS. Oncofertility in the setting of advanced cervical cancer – A case report. Gynecol Oncol Rep 2018;24:27-29.

154. Longoria TC, Tewari KS. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opin Drug Metab Toxicol 2018; 14:543-50.

155. Pfaendler KS, Liu MC, Tewari KS. Bevacizumab in cervical cancer: 5 years after. Cancer J 2018;24:187-92.

156. Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 2018;151:257-63.

157. Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O’Malley DM, Robison K, Miller DS. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: A phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2018;36:3324-30.

158. Pearre DC, Tewari KS. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Ther Clin Risk Manag 2018;14:2189-2201.

159. Liu MC, Tewari KS. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. 2018 Dec27;7:212558.

160. Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma. Obstet Gynecol 2019;133:245-54.

161. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Albert DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Secord AA, Rubin SC, Mannel RS. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2019;37:1380-90.

162. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Byoung-Gie K, Powell MA, O’Malley DM, Spirtos NM, Small Jr W, Tewari KS, Richards WE, Nakayama J, Miller DS. Adjuvant chemotherapy/radiation for locally advanced endometrial cancer. N Engl J Med 2019;380:2317-26.

163. Tewari KS. Immune checkpoint blockade in PD-L1+ platinum-refractory cervical carcinoma. J Clin Oncol 2019;37:1449-54.

164. Runge AS, Bernstein ME, Lucas AN, Tewari KS. Cervical cancer in Tanzania: A systematic review of current challenges in six domains. Gynecol Oncol 2019;29:40-7.

165. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Chenglin Y, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 2019;37:2317-28.

166. Tewari KS, Monk BJ. Evidence-based treatment paradigms for management of invasive cervical carcinoma. J Clin Oncol 2019;37:2472-89.

167. Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol 2019;155:69-74.

168. Tewari KS. Minimally invasive surgery for early-stage cervical carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results. J Clin Oncol 2019;37:3075-80.

169. Haunschild C, Tewari KS. Bevacizuamb use in the frontline, maintenance, and recurrent settings for ovarian cancer. Future Oncol 2019 Nov 20 [Epub ahead of print].

170. Tewari KS. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3. J Gynecol Oncol 2019;30:e119.

171. Tewari KS, Monk BJ, Burger RA. Reply to Farolfi et al and to Haines et al. J Clin Oncol 2020;38:173-4.

172. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim B-G, Fujiwara K, Walker JL, Flynn PJ, Secord AA, Rubin S, Chan JK, Di Silvestro P, Davidson SA, Cohn DE, Tewari KS, Brady MF, Mannel RS. Secondary surgical cytoreduction in recurrent ovarian cancer. N Engl J Med 2019;381:1929-39.

173. O’Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND#14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol 2019;155:393-9.

174. Chinn J, Tewari KS. Multimodality screening and prevention of cervical cancer in sub-Saharan Africa: a collaborative model. Curr Opin Obstet Gynecol 2020;32:28-35.

175. Liu MC Gardner AB, Wolford JE, Tewari KS. Endometrial cancer in the morbidly obese: a review. Curr Opin Obstet Gynecolol 2020;32:42-50.

176. Coakley K, Wolford J, Tewari K. Fertility preserving treatment for gynecologic malignancies. Curr Opin Obstet Gynecol 2020;32:51-56.

177. Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O’Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218. Clin Cancer Res 2020 Jan 9 [Epub ahead of print].

178. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NERG Oncology Group study. Int J Gynecol Cancer 2020 Feb 28 [Epub ahead of print].

179. Clair K, Tewari KS. Robotic surgery for gynecologic cancers: Indications, techniques and controversies. J Gynecol Oncol 2020 (in press).

180. Wolford E, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecol Oncol 2020 (in press).

JOURNAL ARTICLES, NON-PEER REVIEW

1. Tewari K, Cappuccini F, Freeman RK and DiSaia PJ. Managing cervical cancer in pregnancy. Contemp Ob/Gyn 1999;44:134-43.

2. Tewari KS, Cappuccini F and DiSaia PJ. Molecular biology in gynecologic cancer. Contemp Ob/Gyn 2001;46:84-110.

3. Tewari KS and DiSaia PJ. Radiation oncology: A guide for Ob/Gyns: OBG Management 2001;13:22-33.

4. Tewari KS and Monk BJ. Myths & Facts about Cervical Cancer. What you need to know. Patient Resource Booklet.

5. Tewari KS. Ask the doctor: What is endometrial cancer? Women & Cancer Magazine, Fall Issue, 2007;3:107-9.

6. Tewari KS. Hope shines brightly for ovarian cancer survivors. Women & Cancer Magazine, Winter Issue, 2007;3:62-73.

7. Tewari KS. Highlights from the 39th Annual Meeting of the Society of Gynecologic Oncologists. Women & Cancer website, 2008.

8. Tewari KS. Genetic testing for women at high risk of ovarian cancer. Women & Cancer Magazine, Fall Issue, 2008:4:79-96.

9. Chase DM, Tewari KS. Update on cervical cancer screening. The Female Patient 2010;35:16-21.

10. Tewari KS. Ovarian Cancer Special Edition. The Queen of Hearts Foundation. Women & Cancer Magazine, Fall Issue, 2011;7:36-44.

11. Tewari KS. Supreme Court Ruling a Major Victory for Women’s Health. Guest Editorial, The Female Patient. 2012;37:11-13.

12. Tewari KS. Update on Ovarian Cancer Screening and Diagnostic Tests. Women & Cancer Magazine, Fall Issue, 2012;49-52.

13. Tewari KS (expert commentary). Timely findings from the ovarian tumor tissue analysis consortium. ASCO Post 2013;4:45.

14. Tewari KS. The highlights: Advances in screening and management of ovarian cancer – news from Annual Meetings of the Society of Gynecologic Oncology and the American Society of Clinical Oncology. Women Magazine, Fall Issue 2013;401.

15. Tewari KS. Newly diagnosed with ovarian cancer? Start here. In: Special Report – Ovarian Cancer. Women Magazine, Summer Issue 2014;35-6.

16. Monk BJ, Miller DS, Tewari KS. Reply to W.A.A. Tjalma and J.S. Grossman. J Clin Oncol 2015; 10:966.


OTHER PUBLICATIONS

1. Tewari KS. Creator, Producer, Editor & Staff Contributor for VITAL SIGNS: UC Irvine College of Medicine 12-Month Newsletter, 1992-1993.

2. Tewari KS. Philip John DiSaia, MD: Scientific discovery, surgical philosophy & debate. 1st edition, on the occasion of the Philip J DiSaia Society Annual Meeting, May 2002.

3. Tewari KS. Philip John DiSaia, MD: Scientific discovery, surgical philosophy & debate. 2nd edition, on the occasion of the Philip J DiSaia Endowed Chair Ceremony, October 2002.

4. Tewari KS. Thomas J Garite: Professor & Chairman. 1st edition, on the occasion of the Reception for Professor Garite’s Retirement from the University of California, Irvine, June 2004.

5. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade One: 1937-1947. On the occasion of the 17th Annual Meeting of the Philip J DiSaia, MD Society 19-20 May 2006.

6. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Two: 1947-1957. On the occasion of the 18th Annual Meeting of the Philip J DiSaia, MD Society 11-12 May, 2007.

7. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Three: 1957-1967. On the occasion of the 19th Annual Meeting of the Philip J DiSaia, MD Society 16-17 May, 2008.

8. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Four: 1967-1977. On the occasion of the 19th Annual Meeting of the Philip J DiSaia, MD Society 15-16 May, 2009.

9. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Five: 1977-1987. On the occasion of the 20th Annual Meeting of the Philip J DiSaia, MD Society 17-18 May, 2010.

10. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Six: 1987-1997. On the occasion of the 19th Annual Meeting of the Philip J DiSaia, MD Society 20-21 May, 2011.

11. Tewari KS. Philip John DiSaia – The Gradual Interview: Decade Seven: 1997-2007. On the occasion of the 20th Annual Meeting of the Philip J DiSaia MD Society 18 May 2012.
Professional Societies
2017-2018 Co-Chair – Publications Committee, NRG Onc
2017-present Member, Cervical Cancer Task Force (National Cancer Institute)
2016-present Member, Industry Relations Comm., Society
2016-present Member-at-Large, Nominations Comm., Society of Gynecologic Oncology
2014-present Member, Publications Committee, NRG Oncolo
2014-present Institutional Principal Investigator for NRG Oncology & GOG PARTNERS
2014-present Chairman, Society of Gynecologic Oncology Publications Committee

2018-present Chair – Publications Committee, NRG Oncology
2009-present Member, Amer. Society Gynecologic Laparoscopist
2008-present President, Orange County Ob/Gyn Society
2008-present Member, Committee on Experimental Medicine
2008-present Member, American Association for Cancer Research
2007-present Member, American Society of Clinical Oncology
2006-present Member, American Soc. of Colposcopy & Cervical
2006-present Member, American College of Surgeons
2006-present Member, Society of Gynecologic Oncologists
2006-present Member, Western Assoc of Gynecologic Oncology
2006-present Member, International Society of Gynecologic Ca
Other Experience
Member
St Joseph Cancer Committee 2014

Co-Leader – The Gynecologic Cancer Disease Oriented Team
UC Irvine Health 2014

Co-Chair – Protocol Review & Monitoring Committee
UC Irvine Health 2014

Co-Leader – The Women’s Disease Oriented Team
UC Irvine Health 2012—2014

Member, Executive Committee
UCI Chao Family NCI Designated Comprehensive Cancer Center 2012

Director of Research in Gynecologic Oncology
UC Irvine Health 2011

Program Director, Gynecologic Oncology
St Joseph’s Center for Cancer Prevention and Treatment 2011

Co-Chair, Clinical Trials Protocol Review & Monitoring Committee
UC Irvine Health 2010

Member, Oncology Accelerated Growth Steering Committee
UC Irvine Health 2009

Study Group Member, Seed Grants, 2008 Cycle
Chao Family Comprehensive Cancer Center 2008

Study Group Member, Grants-in-Aid, 2008 Cycle
Chao Family Comprehensive Cancer Center 2008

Director, Shirley Nissen Lectureship in Oncology
Dept Ob/Gyn, UCI 2008

Library Liaison
Dept Ob/Gyn, UC Irvine Health 2007

Moderator, Gynecologic Oncology Section, 30th Annual Review Course in Obstetrics & Gynecology
UC Irvine Health 2007—2007

Co-Chair, Translational Working Group: Cervical Cancer
Chao Family Comprehensive Cancer Center 2007

Judge – 25th Annual Residents’ Paper Day
Department of OB/GYN - UC Irvine Health 2007

Member, Ob/Gyn Residency Selection Committee
Department of OB/GYN, UC Irvine 2007

Member, Clinical Trials Protocol Review & Monitoring Committee
UC Irvine Health 2007

Undergraduate Mentor, BioSci Mentor Program
UC Irvine 2006

Residency Applicant Interviewer
Dept. Ob-Gyn, UC Irvine 2006

Director, Residents’ Colposcopy Clinic
Dept Ob-Gyn, UC Irvine 2006

CME Director, Departmental Grand Rounds
Department of OB/GYN - UC Irvine Health 2006

Graduate Programs
Obstetrics and Gynecology

Last updated
06/09/2020